FLGT
Fulgent Genetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FLGT
Fulgent Genetics, Inc.
A genetic testing and therapeutics company that developing flexible and affordable genetic testing advanced genetic diagnostics tools
Healthcare Technology
05/13/2016
09/29/2016
NASDAQ Stock Exchange
1,313
12-31
Common stock
4399 Santa Anita Avenue, El Monte, CA 91731
--
Fulgent Genetics, Inc. was incorporated in Delaware on May 13, 2016. The company is a technology-based company with a mature clinical diagnostic business and treatment development business. The company's clinical diagnostic business provides molecular diagnostic testing services, comprehensive genetic testing and high-quality anatomical pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. The company's therapeutic development business focuses on the development of drug candidates for the treatment of a variety of cancers using novel nano-encapsulation and targeted therapy platforms designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company's goal is to transform from a genomic diagnostic business to a fully integrated precision medicine company.
Earnings Call
Q1/2025
Estimate EPS-0.18
Actual EPS0.04
Estimate Revenue71.26M
Actual Revenue73.50M
Fulgent Genetics' Q1 2025: Unraveling Contradictions in Revenue Growth, Marketing Strategy, and Diagnostics Performance
May 07,2025 02:36
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.18
Actual EPS0.07
Estimate Revenue76.21M
Actual Revenue81.80M
Fulgent Genetics Q2 2025: Unpacking Contradictions in Anatomic Pathology Growth, Revenue Guidance, and Margins
Aug 01,2025 10:29
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
FLGT has released its 2025 Q3 earnings. EPS was reported at 0.14, versus the expected -0.22, beating expectations. The chart below visualizes how FLGT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FLGT has released its 2025 Q3 earnings report, with revenue of 84.07M, reflecting a YoY change of 17.18%, and net profit of -6.83M, showing a YoY change of 53.55%. The Sankey diagram below clearly presents FLGT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
